-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$7.00302.3% Upside
Gain Therapeutics, Inc. Frequently Asked Questions
-
What analysts cover Gain Therapeutics, Inc.?
Gain Therapeutics, Inc. has been rated by research analysts at Chardan Capital, BTIG in the past 90 days.